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Aspartic proteases play key roles in the biology of malaria parasites and human immunodeficiency virus type
1 (HIV-1). We tested the activity of seven HIV-1 protease inhibitors against cultured Plasmodium falciparum.
All compounds inhibited the development of parasites at pharmacologically relevant concentrations. The most
potent compound, lopinavir, was active against parasites (50% inhibitory concentration [IC50], 0.9 to 2.1 M)
at concentrations well below those achieved by ritonavir-boosted lopinavir therapy. Lopinavir also inhibited the
P. falciparum aspartic protease plasmepsin II at a similar concentration (IC50, 2.7 M). These findings suggest
that use of HIV-1 protease inhibitors may offer clinically relevant antimalarial activity.
The human immunodeficiency virus type 1 (HIV-1) pan-
demic has emerged in many regions of the developing world
already suffering from the burden of malaria (5). In developed
countries, HIV-1 protease inhibitors have dramatically im-
proved the outcome of HIV disease. The target of these in-
hibitors is the HIV-1 protease, a member of the aspartic pro-
tease family (6). Plasmodium falciparum, the most virulent
human malaria parasite, expresses a number of aspartic pro-
teases, known as plasmepsins (2). Recent studies suggest that
three HIV-1 protease inhibitors, saquinavir, ritonavir, and
indinavir, inhibit the growth of Plasmodium falciparum para-
sites in vitro at clinically relevant concentrations (13). In ad-
dition, evidence suggests that HIV-1 protease inhibitors may
protect against malaria through the inhibition of CD36-medi-
ated cytoadherence of P. falciparum-infected erythrocytes (9).
We hypothesized that HIV-1 aspartic protease inhibitors exert
antimalarial activity by acting against plasmepsins. To test this
hypothesis, we investigated the effects of seven available HIV-1
protease inhibitors on the in vitro development of cultured
malaria parasites and on the P. falciparum aspartic protease
plasmepsin II.
To evaluate the antiparasitic effects of HIV-1 protease in-
hibitors, we incubated cultured parasites with multiple concen-
trations of seven inhibitors. P. falciparum parasites were cul-
tured with human erythrocytes (2% hematocrit) in RPMI
medium and 10% human serum (11). Four laboratory strains
of P. falciparum (acquired from the Malaria Research and
Reference Reagent Center) with a wide range of sensitivities
to standard antimalarial drugs were studied (12). Parasites
were synchronized by serial treatments with 5% D-sorbitol
(11). Microwell cultures of synchronized parasites were incu-
bated with HIV-1 protease inhibitors (from 1,000 stocks in
dimethyl sulfoxide [DMSO]; final concentrations ranged from
100 M to 25 nM) for 48 h beginning at the ring stage. The
effects of inhibitors upon P. falciparum morphology were as-
sessed by light microscopy of Giemsa-stained smears. After
12 h of incubation, beginning at the late ring stage, synchro-
nized parasites treated with concentrations of lopinavir achiev-
able with standard dosing (10 M) exhibited markedly altered
morphology (Fig. 1A). Parasite abnormalities were more
marked after 24 h, and after 48 h, when control cultures con-
tained normal rings, treated cultures contained only very ab-
normal pyknotic parasites. The morphological changes caused
by the protease inhibitors were rather nonspecific, but similar
to those caused by the generic aspartic protease inhibitor pep-
statin (1, 10).
To quantify antimalarial activity, new ring stage parasites
were counted after incubating parasites with protease inhibi-
tors for one 48-hour life cycle, beginning at the ring stage. Ring
parasitemias were assessed by fluorescence-activated cell
sorter analysis and compared with those of control cultures
incubated with the same concentration of DMSO, as previ-
ously described (11, 12). Fifty percent inhibitory concentra-
tions (IC50s) were calculated by nonlinear regression with the
Prism 3.0 program (GraphPad Software). All tested HIV-1
protease inhibitors demonstrated antimalarial activity at low
micromolar concentrations (Table 1). Results were similar for
all four tested P. falciparum strains. Calulated IC50s were
higher than those previously reported for the HIV-1 protease
inhibitors saquinavir, ritonavir, and indinavir (13), probably
due to differences in assay methods, but nonetheless all tested
compounds exerted antimalarial activity at concentrations near
those achievable in the bloodstream with standard dosing. Im-
portantly, combination regimens that take advantage of the
boosting of levels of other protease inhibitors by the strong
cytochrome P450 inhibitor ritonavir are increasingly advocated
for standard antiretroviral therapy (8). In this regard, it is of
interest that the most potent antimalarial protease inhibitor
was lopinavir, which demonstrated an IC50 nearly 10-fold be-
low the trough blood concentration achieved with standard
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dosing of a lopinavir/ritonavir combination (Fig. 1B). Ritonavir
also demonstrated potent antimalarial activity at levels achiev-
able with high dosages (600 mg twice daily [b.i.d.]), and at
lower dosage (100 mg b.i.d.) it boosted the levels of several
coadministered protease inhibitors to concentrations at which
antimalarial activity was seen (Table 1). Caution should be
exercised, however, as ritonavir’s potent inhibition of cyto-
chrome P450 may lead to complex drug interactions in coin-
fected patients (4).
The predicted antimalarial mechanism of action of HIV-1
protease inhibitors is the inhibition of plasmepsins. The P.
falciparum genome predicts the existence of 10 plasmepsins.
The best characterized is plasmepsin II, an acidic food vacuole
enzyme that appears to play a role in the initial hydrolysis of
hemoglobin by intraerythrocytic malaria parasites (2). To de-
termine if HIV-1 protease inhibitors also inhibit the P. falci-
parum protease, the effects of lopinavir and ritonavir on the
hydrolysis of a hemoglobin-based peptide substrate by recom-
binant plasmepsin II were assessed. Plasmepsin II was ex-
pressed, purified, and studied as described previously, with the
exception that proplasmepsin II was preactivated for 60 min at
37°C, pH 5.2, and inhibitors were preincubated with enzyme
for 30 min prior to addition of 0.5 M substrate (2). Hydrolysis
was recorded as the increase in fluorescence over 10 minutes
using a Molecular Devices FlexStation II fluorometer. Both
tested protease inhibitors inhibited plasmepsin II at concen-
trations (IC50, 2.7 M for lopinavir and 3.1 M for ritonavir)
near those that were inhibitory for cultured malaria parasites.
However, it remains unclear if the protease inhibitors achieve
adequate intracellular concentrations to inhibit plasmepsin II,
and additional studies will be needed to fully characterize their
specific enzymatic targets.
Antiretroviral therapy is increasingly available to HIV-in-
fected individuals in malaria-endemic regions. Currently, non-
nucleoside reverse transcriptase inhibitor (NNRTI)-based reg-
imens are preferred because of cost, simplicity of dosing,
modest storage requirements, and availability of coformulated
preparations (15). However, protease inhibitors are advocated
in some regions where the HIV type is insensitive to NNRTIs
and for the treatment of viruses that are resistant to other
classes of drugs. The use of protease inhibitors will likely in-
crease as NNRTI resistance rises and as protease inhibitor
regimens are simplified (15).
Our results support the intriguing possibility that HIV-in-
fected individuals receiving protease inhibitor therapy may
also benefit from an antimalarial effect due to inhibition of
plasmepsins. In vitro, lopinavir demonstrated potent activity
against P. falciparum at concentrations well below those
achievable with standard dosing of a ritonavir-boosted lopina-
FIG. 1. Effects of HIV-protease inhibitors on cultured parasites. A.
Parasite morphology. Synchronized ring stage parasites were incu-
bated with 10 M lopinavir. Treated and control (with equivalent
concentrations of DMSO) parasites were evaluated at the indicated
time points on Giemsa-stained smears. B. Parasite development. Syn-
chronized parasites were incubated with multiple concentrations of
lopinavir, beginning at the ring stage. After 48 h, ring parasitemias
were determined by flow cytometry analysis of YOYO-1-stained par-
asites, as previously described (11). Results represent two independent
experiments, each performed in duplicate using the HB3 strain of P.
falciparum. Error bars represent standard deviations.
TABLE 1. Activity of HIV-1 protease inhibitors against cultured P. falciparumh
Drug
P. falciparum IC50 (M) for:
Serum concn (M) with:
Standard dosing Ritonavircoadministration
HB3 D6 Dd2 W2 Cmax Cmin Cmax Cmin
Saquinavira 5.6  0.4 4.8 1.2 4.3 1.2 1.1 0.5 3.7 0.3 5.5 0.6
Ritonavirb 4.7  0.2 7.9 1.9 6.9 2.5 1.2 0.5 15.5 5.1 NA NA
Indinavirc 5.8  0.9 15.6 2.6 31.2 9.4 4.1 2.4 10.3 0.3 17.2 0.4
Nelfinavird 15.2  0.1 23.0 3.5 19.1 5.5 6.5 2.3 6.0 3.3 NA NA
Amprenavire 51.9  22.4 25.0 8.3 17.4 12.2 33.3 6.6 15.2 0.6 14.1 3.8
Lopinavirf 1.4  0.2 2.0 0.4 2.1 0.2 0.9 0.2 NA NA 15.6 8.8
Atazanavirg 6.8  0.3 11.6 2.5 7.1 1.3 2.5 1.0 3.3 0.2 8.7 1.7
a Based on saquinavir 1,200 mg three times daily (as free base) in HIV-infected individuals and coadministered saquinavir soft gel capsule 1,000 mg/ritonavir 100
mg b.i.d. in HIV-infected individuals (Roche prescribing information) (14).
b Based on ritonavir 600 mg b.i.d. in healthy and HIV-infected individuals (Abbott prescribing information).
c Based on indinavir sulfate 800 mg every 8 h and coadministered indinavir 800 mg/ritonavir 100 mg b.i.d. in healthy individuals with low-fat meal (3).
d Based on nelfinavir mesylate 1,250 mg b.i.d. in HIV-infected individuals; Cmin was determined prior to morning dosage (Agouron prescribing information).
e Based on amprenavir 1,200 mg b.i.d. in healthy individuals and coadministered amprenavir 600 mg/ritonavir 100 mg b.i.d. in HIV-infected individuals (Glaxo-
SmithKline prescribing information) (7).
f Based on lopinavir 400 mg/ritonavir 100 mg b.i.d. in HIV-infected individuals (Abbott prescribing information).
g Based on atazanavir sulfate 400 mg once a day (q.d.) in HIV-infected subjects and coadministered atazanavir 300 mg/ritonavir 100 mg q.d. (Bristol-Myers Squibb
prescribing information); serum concentrations are given as geometric means of atazanavir, as free base.
h IC50 data are means  standard deviations from four experiments. Serum concentrations are from published information. Cmax and Cmin are the mean maximum
and minimum serum levels achieved under standard dosing intervals, respectively. Ritonavir-boosted serum concentrations are those achieved with coadministration
with ritonavir, as indicated in the other footnotes. NA, not applicable, as these formulations are not used clinically.
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vir regimen. Due to concerns regarding cost, toxicity, and po-
tential selection of resistant viruses, it is unlikely that currently
available HIV-1 protease inhibitors will gain roles as standard
treatments for malaria. Nonetheless, it seems likely that, for
select protease inhibitors, the concentrations achieved during
chronic antiretroviral therapy will offer some protection
against malaria. If standard regimens for HIV-1 offer chemo-
prophylaxis against malaria, particularly in children, in whom
the burden of malaria is greatest, the clinical consequences of
this effect will be great. However, it is unclear if in vitro results
showing antimalarial activity of HIV-1 protease inhibitors pre-
dict clinical efficacy. Therefore, clinical trials to test the hy-
pothesis that HIV-1 protease inhibitors confer protection
against malaria are urgently needed.
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